Amulet Capital Partners, a private equity investment firm specialising in the healthcare sector, has announced the closure of Amulet Capital Fund III with approximately $1.2bn in capital commitments.
The fund, which was oversubscribed, includes commitments from a range of global institutional investors such as state and corporate pension funds, endowments, foundations, and family offices. With this closing, Amulet now manages approximately $2.7bn in assets.
Fund III will build on Amulet’s value-oriented, thesis-driven investment strategy and its previous successes. The fund will continue to invest in high-growth subsectors within the life sciences outsourcing, healthcare provider, and payor services ecosystems.
Amulet’s investment approach is designed to be flexible, allowing the firm to work with management teams to create long-term value.
Amulet president and managing partner Ramsey Frank said: “We are grateful to have received such strong support from our existing and new investors and are pleased to have closed Fund III significantly above target.
“This marks the third consecutive above-target raise for our firm, which we view as a testament to our consistent investment philosophy and the strength of the value-creation framework we’ve built and successfully implemented across our portfolio consistently throughout cycles.”
Amulet managing partner Jay Rose said: “This successful capital raise reflects the deep expertise of our team, network and track record of delivering positive outcomes. We believe the unique – and often underinvested – subsectors we’ve identified represent significant opportunity for Fund III.
“We are excited to continue strategically deploying capital to help build best-in-class businesses and drive meaningful change and innovation for patients, physicians and the broader healthcare landscape across the country.”
Amulet has already made two new platform investments with Fund III.
One of them is minds + assembly, a design-centric agency and commercialisation platform serving the pharmaceutical, biotech, and digital health industries.
The second investment was in Alliance Clinical Network, a clinical platform that supports patients, pharmaceutical sponsors, and contract research organisations (CROs) in various clinical areas, including dermatology, neurology, gastroenterology, pain, vaccines, and women’s health.
Capstone Partners, a Mizuho Company, acted as the exclusive placement agent for Fund III, while Kirkland & Ellis served as legal counsel to Amulet.
